Amneal receives FDA approval for generic Indocin
BRIDGEWATER, N.J. — The Food and Drug Administration has approved a generic drug for pain and inflammatory diseases made by Amneal Pharmaceuticals, Amneal said Thursday.
The FDA approved indomethacin extended-release capsules in the 75-mg strength. The drug is used to treat pain associated with rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, bursitis and tendonitis.
The drug is a generic version of Merck’s Indocin. Annual sales of indomethacin ER capsules were $41.5 million during the 12-month period ended in October 2010, according to IMS Health.
Spring sports physicals now available at MinuteClinic
WOONSOCKET, R.I. — MinuteClinic announced that it is offering spring sports physicals at its facilities across the country to make it easier and more affordable for children and teenagers to head to the field and participate in organized sports.
Beginning March 1 to 31, MinuteClinic will offer the pre-participation physicals, which are required by many states, school systems and athletic leagues. MinuteClinic nurse practitioners and physician assistants will offer the exams seven days a week, including weekday evenings. No appointment is necessary.
Coaches, team leaders and athletic directors also can take advantage of an additional $5 team discount.
Once a child is cleared to play, MinuteClinic practitioners will stamp any required forms and reference the results provided on the official patient summary. Copies of the summary can be transmitted by electronic record, fax or mail to a primary care provider with patient permission.
In addition to sports physicals, MinuteClinic offers camp, college and Department of Transportation physicals on a daily basis at about 500 select CVS/pharmacy locations around the country.
Endo launches Fortesta
CHADDS FORD, Pa. — Endo Pharmaceuticals has launched a recently approved testosterone gel for men.
Endo announced Thursday the launch of Fortesta, approved by the Food and Drug Administration for treating low testosterone — or low T — in men, which affects about 14 million men in the United States; around 1.3 million of those men currently are receiving treatment, according to Endo.
“We are excited to bring Fortesta gel to market in the United States and are confident that once men try it, Fortesta gel will quickly become a significant treatment option for many men with low T,” Endo COO Julie McHugh said.